轩竹生物-B(02575)发布公告，经公司提名委员会推荐，徐艳君女士已获委任为公司总经理，自2026年1 月5日起生效。 ...

智通财经APP讯，轩竹生物-B(02575)发布公告，经公司提名委员会推荐，徐艳君女士已获委任为公司总 经理，自2026年1月5日起生效。 ...

格隆汇1月5日丨轩竹生物-B(02575.HK)宣布，经公司提名委员会推荐，徐艳君获委任为公司总经理，自 2026年1月5日起生效。 ...

董事名單與其角色及職能 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （股份代號：2575） （一家於中華人民共和國註冊成立的股份有限公司） 軒 竹 生 物 科 技 股 份 有 限 公 司 董 事 會（「董事會」）成 員 載 列 如 下： 執行董事 徐艷君女士 （董 事 長 兼 總 經 理） 李嘉逵博士 史澂空博士 獨立非執行董事 劉碩先生 王宇女士 范智超先生 董 事 會 下 設 三 個 委 員 會。下 表 載 列 各 董 事 會 成 員 在 該 等 委 員 會 中 所 擔 任 的 職 位。 | | 委員會 | | 薪酬與 | | | | | --- | --- | --- | --- | --- | --- | --- | | 董 事 | | 審計委員會 | 考核委員會 | | | 提名委員會 | | 徐艷君女士 | | | 成 | 員 | 成 | 員 | | 李嘉逵博士 | | | | | | | | 史澂空博士 | | | | | | | | 李惠英女士 | | | | | | | | 尉麗峰先生 | | | | | | | | 陳燕玲女士 | 成 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 委任總經理 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈，經 本 公 司 提 名 委 員 會 推 薦，徐 艷 君 女 士（「徐女士」） 已 獲 委 任 為 本 公 司 總 經 理，自 二 零 二 六 年 一 月 五 日 起 生 效。 徐 女 士 作 為 本 公 司 總 經 理 的 任 期 自 二 零 二 六 年 一 月 五 日 起 計，為 期 三 年。徐 女 士 已 就 擔 任 執 行 董 事 與 本 公 司 訂 立 服 務 合 約，任 期 自 二 零 二 五 年 九 月 五 日 起 計，不 超 過 三 年。徐 女 士 作 為 本 公 司 總 經 理 將 不 會 收 取 額 外 薪 酬。 根 據 香 港 聯 合 交 易 所 有 限 公 司 ...

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median increase for the top 10 innovative drug companies was 57.9%, with the highest increase reaching 132.6%. In 2025, this trend intensified, with the median increase for the top 10 soaring to 495.41% and the highest increase hitting 1824% [2] Group 1: Top Performing Companies - Beihai Kangcheng-B achieved the highest increase in 2025, with a staggering 1824% rise, surprising many in the market [5] - Sanleaf Biotech-B followed with an impressive 870% increase, despite facing significant operational challenges, including a cash flow crisis and a major refund demand from GAVI [10][11] - Yaojie Ankang-B, despite being controversial, saw its stock price rise nearly ninefold in a short period, reaching a market cap close to 270 billion HKD [12][13] - Heptagon Pharmaceuticals-B ranked fourth with a 553% increase, driven by its dual-engine model of R&D and business development [14][15] - Xuan Bamboo Biotech-B, a newly listed company, achieved a 507% increase, benefiting from positive clinical trial results and inclusion in national insurance directories [17][18] - Deqi Pharmaceuticals-B saw a 483% increase, attributed to its innovative AI-driven T-cell connector platform [19][20] - Jike Si-B experienced a 401% increase, driven by its advancements in KRAS-targeted therapies [22][23] - Rongchang Biotech achieved a 400% increase, with its product Taite Xip demonstrating significant potential across multiple indications [24][25] - Paige Biotech saw a 342% increase, largely due to its GLP-1 pipeline's market momentum [27] - Baiaosaitu-B rounded out the top ten with a 315% increase, supported by strong revenue growth and positive market expectations for its upcoming H+A listing [28][30] Group 2: Market Dynamics - The surge in stock prices for many companies is not solely based on fundamental improvements but also reflects speculative trading behaviors [4] - The innovative drug sector's long-term health relies on the emergence of stocks driven by genuine innovation rather than short-term speculation [4] - The market's focus on liquidity and sentiment has led to significant price increases, but these may not be sustainable as market conditions change [31]

轩竹生物-B(02575)发布公告，李嘉逵博士辞任本公司执行董事及总经理，以投放更多时间于其他业务 承担。 为确保企业管治及董事会运作顺利过渡，李博士承诺会继续忠实及勤勉尽责地履行执行董事职责。辞任 仅于本公司股东大会委任新执行董事加入董事会后生效。 ...

为确保企业管治及董事会运作顺利过渡，李博士承诺会继续忠实及勤勉尽责地履行执行董事职责。辞任 仅于本公司股东大会委任新执行董事加入董事会后生效。 智通财经APP讯，轩竹生物-B(02575)发布公告，李嘉逵博士辞任本公司执行董事及总经理，以投放更多 时间于其他业务承担。 ...

格隆汇1月2日丨轩竹生物-B(02575.HK)宣布，李嘉逵辞任公司执行董事及总经理，以投放更多时间于其 他业务承担。 ...